Allergan settles with Famy Care over patent litigation

Allergan has reached a settlement regarding its litigation with Famy Care Limited relating to certain Allergan’s United States Patent covering Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%.

The patents are listed in the Orange Book and expire on August 27, 2024.

As a result of the settlement, all Famy Care litigation regarding Restasis patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review. Allergan will grant Famy Care a license to market a generic version of Restasis in the United States beginning on February 27, 2024, or earlier under certain circumstances, the company said.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.